debt_leverage_profile
Minimal debt; Kazia is a clinical-stage biotech funded primarily by equity raises and grants, near-zero leverage ratio
Inferred
Agent_Inference
interest_rate_sensitivity
Negligible direct impact; no material floating-rate debt, though higher rates increase cost of future equity dilution rounds
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
1) US FDA/CRO clinical trial site access; 2) Australian GMP API manufacturers for paxalisib synthesis
Inferred
Agent_Inference
international_expansion_readiness
Revenue near-zero; grant income in AUD, USD exposure via US trials; minimal sovereign currency devaluation risk currently
Inferred
Agent_Inference
geographic_footprint
Primarily Australia (AUD) and USA (USD); AUD depreciation vs USD slightly benefits USD-denominated grant receipts
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Single CRO partners for paxalisib trials likely represent >30% of operational cost; non-trivially substitutable mid-trial
Inferred
Agent_Inference
business_model_type_primary
Clinical-stage biotech; no cloud-critical revenue ops; cloud termination would disrupt data management but not core drug development
Inferred
Agent_Inference
business_model_type_secondary
Preclinical/clinical R&D with licensing/partnership monetization intent; secondary model is asset-out partnering with pharma majors
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; no customer-facing software product; CRO switching mid-trial carries high regulatory and cost risk
Inferred
Agent_Inference
howey_test_risk_index
Low Howey risk; revenue model is drug licensing/grants, not token or investment-contract based
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Moderate; clinical trial patient data across US, EU, Australia requires GDPR and HIPAA compliance; no CCPA revenue exposure
Inferred
Agent_Inference
antitrust_exposure_flag
Negligible; single-asset clinical-stage company with no market share in commercialized oncology products
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
~100% non-recurring; revenue consists of sporadic grants and milestone payments, no subscription or retainer income
Inferred
Agent_Inference
monetization_vector
Future monetization via out-licensing paxalisib or GBM-related assets to large pharma; no current commercial revenue
Inferred
Agent_Inference
pricing_architecture
No current commercial pricing; future drug pricing subject to oncology market comps (~$100K–$300K/year per patient for GBM therapies)
Inferred
Agent_Inference
pricing_power_rating
Potential high pricing power if paxalisib achieves FDA approval in orphan GBM indication; unproven until commercialization
Inferred
Agent_Inference
target_gross_margin_bracket
Royalty/licensing model targets 80–90% gross margin; manufacturing COGS would apply only if self-commercializing
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider risk; IP-protected drug candidate with no open-source or public-good leakage exposure
Inferred
Agent_Inference
headcount_cost_structure
Revenue growth is highly sublinear to headcount; licensing milestones do not require proportional staff increases
Inferred
Agent_Inference
marginal_cost_of_growth
Near-zero marginal cost for licensing revenue; incremental trial expansion costs are fixed CRO contracts, not headcount-driven
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; Kazia has no franchise network
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale (licensing deals), BD cost per deal remains low; primary constraint is clinical data quality, not CAC
Inferred
Agent_Inference
network_effect_present
No network effects; drug efficacy data value grows with trial size but is not a traditional network effect
Inferred
Agent_Inference
asset_efficiency_ratio
AI displacement risk low for core drug; AI could accelerate companion diagnostics or biomarker identification for paxalisib
Inferred
Agent_Inference
recession_resistance_tier
Moderate resilience; GBM is a fatal indication with no good alternatives, sustaining trial enrollment; funding rounds harder in downturns
Inferred
Agent_Inference
customer_segment_primary
Large pharmaceutical and biotechnology companies as potential licensing partners/acquirers
Inferred
Agent_Inference
customer_segment_secondary
Government and philanthropic grant bodies (NCI, Cancer Australia) providing non-dilutive R&D funding
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
Capital reallocated toward paxalisib Phase 2 GBM trials; legacy EVT801 program de-prioritized; future-state infrastructure is clinical data assets
Inferred
Agent_Inference
sec_cik
0001075880
High
SEC-EDGAR
ticker
KZIA
High
SEC-EDGAR